Breaking News From Pharma & Bio Ingredients
DOV Initiates Phase I Trial for Depression
Posted on 2005-02-24 06:06:00
DOV Pharmaceutical, Inc., Hackensack, NJ, has initiated the first Phase I clinical trial with DOV 102,677, believed to be a potent inhibitor of serotonin, norepinephrine and dopamine reuptake, with preferential action on the dopamine transporter protein. DOV 102,677 is the third of DOV's triple reuptake inhibitors to enter the clinic. This clinical trial is a double-blind, randomized, placebo controlled study to evaluate the safety, pharmacokinetics and pharmacodynamics of a range of escalating single doses of DOV 102,677 in healthy volunteers. The trial is being conducted under a U.S. investigational new drug application (IND).
No currently marketed antidepressant inhibits the reuptake of all three neurotransmitters linked to depression: serotonin, norepinephrine and dopamine. Both preclinical studies and clinical trials indicate that a drug inhibiting reuptake of all three such neurotransmitters will produce more rapid onset of action and greater efficacy than traditional antidepressants. DOV believes that such a "broad spectrum" antidepressant could represent a breakthrough in the treatment of depression. Based upon preclinical studies, DOV 102,677 has potential utility in the treatment of depression, attention deficit disorder and obesity.
Dr. Phil Skolnick, DOV's senior vice president, research and chief scientific officer, stated, "DOV 102,677 is the second compound from our internal preclinical discovery program to enter the clinic, with DOV 21,947 the first. We are excited to advance this compound into the clinic because it both underscores the robustness of our discovery programs and validates our strategy of relying, in part, on our internal discovery effort to fuel our pipeline. Following completion of this clinical trial, we intend, in 2005, to initiate two additional Phase I clinical trials and a Phase II clinical trial for DOV 102,677."
Subscribe via RSS
